Skin Therapy Letter
Written by Dermatologists for Dermatologists
- Website
- skintherapyletter.com · all feeds from this site
- Feed URL
https://www.skintherapyletter.com/feed/
Read it in your FeedListing reader
Or add to: Feedly Inoreader Raw feed
Latest posts
-
Delgocitinib Cream for Chronic Hand Dermatitis: Efficacy, Safety and Clinical Application
Delgocitinib 2% cream is the first topical pan-JAK inhibitor approved for moderate-to-severe chronic hand dermatitis. This review covers its mechanism, phase 2 and DELTA 1–3 trial results, long-term safety without a boxed warning, and its role as a steroid-sparing option in…
-
Emerging Topical Therapies and Skin Care Management for Hidradenitis Suppurativa
Mild hidradenitis suppurativa still has no approved treatments. This review covers emerging topical options for Hurley stage I disease, including ruxolitinib, roflumilast and clascoterone, plus new HS cleansers and a Catalytic Treatment Matrix for faster wound healing after…
-
Update on Drugs & Devices: September-October 2026
Update on dupilumab (Dupixent®), now FDA-approved for chronic spontaneous urticaria in children 2-11 years, and adapalene 0.1% + benzoyl peroxide 2.5% (Differin® Epiduo® Acne Gel), now OTC. Plus: bemotrizinol, the first new FDA sunscreen filter in 20+ years, and a Health Canada…
-
Molluscum Contagiosum: A Review and Update on New Treatments
Most molluscum contagiosum lesions resolve on their own, but symptomatic or cosmetically troubling cases have long been managed with off-label agents and destructive procedures. That changed with the FDA approval of cantharidin 0.7% drug-device applicator in 2023 and berdazimer…
-
More Than Skin Deep: Understanding the Skin-Bone Axis
The skin has long been read as a mirror of internal disease, but its relationship with bone is less familiar. Dermis and bone share a common embryonic origin, overlapping cell lineages, and collagen as a structural backbone. This review examines the skin-bone axis — vitamin D…
-
Update on Drugs & Devices: July-August 2026
Update on Dupilumab for SC injection (Dupixent®) and Adapalene 0.1% + benzoyl peroxide 2.5% acne treatment (Differin® Epiduo® Acne Gel). Also, in June 2026, bemotrizinol – long used internationally as Tinosorb® S – has become the first new FDA‑approved sunscreen filter in over…
-
Exosomes in Dermatology
Exosomes are emerging as a promising biologic platform in dermatology, with growing evidence supporting their role in wound healing, skin regeneration, pigmentation control, and inflammatory skin disorders through immune modulation and tissue repair mechanisms.
-
Zasocitinib: New Frontier in Tyrosine Kinase 2 Inhibition
Discover how zasocitinib, a next-generation selective TYK2 inhibitor, may redefine psoriasis treatment with targeted efficacy, reduced off-target JAK effects, and promising late-stage clinical results.
-
Update on Drugs & Devices: May – June 2026
Update on Icotrokinra 200 mg tablet (Icotyde™), Difamilast 1% ointment (Adquey™), and Epinephrine nasal spray 2 mg/0.1 mL (Neffy®).
-
Erratum to: Deuruxolitinib for Alopecia Areata
Erratum to the deuruxolitinib for alopecia areata review, including revised safety data, launch information, and clinical comparisons.